Scienture Holdings, Inc. Unveils Its New Corporate Identity
In a notable step that signals its growth and strategic shift, the company previously known as TRxADE Health, Inc. has revealed its new name and ticker symbol. From now on, it will be referred to as Scienture Holdings, Inc., and its stock will trade under the ticker symbol 'SCNX' on the Nasdaq Stock Market.
A Fresh Beginning
Starting on September 23, 2024, Scienture Holdings, Inc. embarked on this transformation, emphasizing a renewed commitment to its mission and market focus. This change marks an exciting new chapter for the company and everyone involved.
Services and Product Offerings
Scienture Holdings operates through its subsidiaries, Scienture and Integra Pharma Solutions, LLC (IPS). With a commitment to developing groundbreaking pharmaceutical products that address unmet medical needs, they work across various therapeutic areas, ensuring patients, healthcare providers, and caregivers receive comprehensive support through specialized products.
Meet the Leadership Team
The leadership team at Scienture Holdings is made up of experienced professionals who bring a wealth of knowledge from the pharmaceutical industry. Their expertise is key in shaping the company's vision and guiding its product development:
- Suren Ajjarapu: CEO and Chairman of the Board
- Prashant Patel: President as well as Interim CFO and COO
- Shankar Hariharan, Ph.D.: CEO of Scienture
- Narasimhan Mani, Ph.D., MBA: President of Scienture
- Donald Fell, Mayur Doshi, Subbarao Jayanthi: Board Members
Discovering Scienture, LLC and Integra Pharma Solutions
Scienture, LLC is headquartered in New York and features a team of industry veterans who are passionate about delivering innovative pharmaceutical solutions. Their development efforts are aimed at adding value for both healthcare providers and patients while continually addressing market needs.
Integra Pharma Solutions, LLC is recognized as a reliable supplier, with a strong presence in the distribution of therapeutic products across various healthcare sectors. They excel in providing pharmaceuticals, medical supplies, and more, playing a vital role in improving pharmaceutical access across the nation.
Important Considerations
As is the case with any corporate transition, stakeholders should stay informed about the potential risks tied to forward-looking statements and market dynamics. Like many other companies in the industry, Scienture Holdings faces challenges such as regulatory compliance, funding availability, and competition in the marketplace.
How to Get in Touch
If you’re looking to connect or seek further information, here are the contact details for Scienture Holdings, Inc. and Scienture, LLC:
Scienture Holdings, Inc.
6308 Benjamin Rd, Suite 708
Tampa, Florida 33634
Phone: (866) 468-6535
Email: IR@Rxintegra.com
Scienture, LLC
20 Austin Boulevard
Commack, New York 11725
Phone: (631) 670-6039
Email: IR@Scienture.com
Frequently Asked Questions
1. Why did Scienture Holdings change its name?
The name change represents a new strategic focus and a dedication to enhancing value within the pharmaceutical sector.
2. When did the ticker symbol change take effect?
The ticker symbol change was effective starting September 23, 2024, with the new ticker being 'SCNX'.
3. Who are the notable members of the leadership team at Scienture Holdings?
The leadership team features experienced professionals like Suren Ajjarapu, Prashant Patel, and Shankar Hariharan, Ph.D.
4. What kind of products does Scienture Holdings develop?
Scienture Holdings develops specialty pharmaceutical products that cover various therapeutic areas, specifically targeting unmet medical needs.
5. How can stakeholders reach Scienture Holdings?
Stakeholders can contact Scienture Holdings via the provided email addresses or phone numbers for both Scienture Holdings, Inc. and Scienture, LLC.
